More Truths about Truvada: it's a combined HIV drug comprising Emtriva and Viread

sharing this page from Carl Grinde's Blog:
 Now, for the first time, adults who do not have HIV but are at risk of becoming infected can take a medication to reduce the risk of sexual transmission of the virus.
Truvada is made by Gilead.

http://www.gilead.com/pr_933190157

Truvada is made by Gilead. Side effects: "new or worsening kidney problems, thinning of the bones (osteopenia), which could lead to fractures, inflammation, diarrhea, dizziness, nausea, headache, fatigue, abnormal dreams, sleeping problems, rash, depression, changes in the distribution of body fat, stomach area (abdomen) pain, headache, a buildup of acid in the blood (lactic acidosis), decreased weight, Serious liver problems (hepatotoxicity), with liver enlargement (hepatomegaly), and fat in the liver (steatosis). Symptoms of liver problems include your skin or the whites of your eyes turning yellow (jaundice), dark colored urine, light colored stools, lack of appetite, nausea, and/or pain in your lower stomach area. In some cases, these serious conditions have lead to death." 
Quotes from www.truvada.com 

The Shame of Gilead

by Terry Michael

Gilead Sciences, headquartered in Foster City, CA, is the world's number one purveyor of the chemotherapies known as "anti-retrovirals" (ARVs.) In 2011, the company (named for the Biblical "balm of Gilead") reported ARV sales of about $6.91 billion dollars. The trade names for their ARVs are: Truvada, Atripla, Viread, Complera and Emtriva--all of which they acknowledge have serious adverse "side" effects (as noted in the Gilead prescribing information for Truvada.) Gilead was way ahead of nearest competitor Bristol-Myers-Squibb, which sold about $3.05 billion of the chemo in 2011, according to year-end corporate reports I have reviewed.

Gilead could change the game for HIV patients

FOLLOW THE $$ 

San Francisco Business Times - by Ron Leuty

Date: Friday, December 31, 2010, 3:00am PST

Biotech: Pill to watch-Gilead Sciences' Quad pill

Read more: Biotech: Pill to watch-Gilead Sciences' Quad pill | San Francisco Business Times

 Foster City-based Gilead could change the game for HIV patients and its bottom line, adding a new drug and booster to its once-a-day pill.

The so-called Quad pill and its elements are undergoing three Phase III studies. A fourth 700-patient trial is enrolling.

About half of the HIV patients who start therapy in the United States already use Gilead’s three-in-one Atripla, which uses Bristol-Myers Squibb’s Sustiva. The Quad pill drops the Bristol-Myers Squibb drug and uses Viread, Emtriva and a new Gilead drug called elvitegravir plus an elvitegravir booster.

Wall Street analysts have pegged the pill as a $4 billion-a-year ...

Read more: Biotech: Pill to watch-Gilead Sciences' Quad pill | San Francisco Business Times